FDA's new rare disease framework: What it means for drug developers

A new approach to rare disease development

Developing treatments for rare diseases comes with unique challenges that traditional drug development approaches are not always designed to address . Patient populations are small, natural-history data can be limited and meaningful clinical outcomes are often difficult to measure. Even promising therapies can struggle to generate the evidence needed for regulatory approval.

The US Food and Drug Administration (FDA) wants to address these challenges more systematically.

On 16 October 2026, the agency published a Federal Register notice on its Fit-for-Purpose Rare Disease Framework Initiative, launching a consultation on how rare disease therapies are developed and reviewed. The aim is to make regulatory expectations more consistent while allowing evidence requirements to reflect the characteristics of individual diseases.

No regulations have changed yet. The FDA is seeking input on four topics: fit-for-purpose review, consistency of requirements across review divisions, engagement with patients and disease experts, and chemistry, manufacturing and controls (CMC). Its decisions on implementation will follow the consultation.

Why change is needed

Roughly 1 in 10 Americans lives with a rare disease, according to the FDA's notice, yet only approximately 5% of recognised rare conditions have an FDA-approved treatment.

Progress has been substantial in some areas. In 2025, 25 of the 46 novel drugs approved by the FDA's drug centre (CDER) had orphan designation, and the agency operates numerous programmes supporting rare disease development. However, the FDA acknowledges that progress has not kept pace with the scale of unmet need.

This is why more efficient development pathways matter, provided that standards for safety and effectiveness remain intact.

Five changes that could make a difference

The proposed framework builds on practices already used by the FDA. Its main ambition is to make them more consistent, transparent and accessible across review divisions.

1. Evidence requirements tailored to the disease

Traditional clinical trial designs are not always feasible when only a few hundred patients are known worldwide, disease progression varies considerably and validated endpoints are unavailable.

The FDA wants reviewers to apply fit-for-purpose evidence approaches more consistently, taking account of the disease, patient population and proposed treatment.

For developers, clearer expectations earlier in development could reduce uncertainty about the evidence regulators will require.

2. Earlier involvement of patients

Patients and families understand aspects of a disease that clinical assessments may not fully capture. Their experiences can help identify the symptoms that matter most, meaningful treatment benefits and acceptable risks.

The FDA already collects patient perspectives, but the framework proposes involving patients earlier and at defined milestones throughout development and review.

This creates an opportunity for sponsors to incorporate patient perspectives into clinical development decisions from the outset, rather than seeking input after key decisions have been made.

3. Greater involvement of disease experts

In ultra-rare diseases, specialist knowledge is often concentrated among a small number of clinicians and researchers.

These experts can provide essential context when natural-history evidence is incomplete or patient populations are highly variable.

The FDA proposes making external expertise a more systematic part of regulatory review, helping reviewers interpret evidence in the context of each disease.

4. Risk-based manufacturing and inspection requirements

The framework also addresses chemistry, manufacturing and controls (CMC) reviews and pre-approval inspections.

The FDA intends to explore risk-based approaches that could reduce unnecessary delays while maintaining appropriate quality and safety standards.

For developers of complex biological therapies, manufacturing readiness remains an important consideration alongside clinical development.

5. Better coordination within the FDA

Finally, the agency wants to consolidate rare disease expertise across its drug and biologics centres.

Shared knowledge, training and resources could improve consistency between review teams and help sponsors navigate regulatory expectations.

The initiative covers development from early regulatory discussions through to post-approval obligations. Its eventual outcomes may include revised guidance, internal procedures or regulatory provisions.

Why the wider disease ecosystem matters

One of the most interesting aspects of the FDA's proposal is its recognition that evidence generation depends on more than the company developing a treatment.

Patients, treating physicians, specialist researchers and clinical centres all contribute knowledge that can shape development decisions.

In rare diseases, these relationships are particularly important.

A handful of hospitals may treat most diagnosed patients. Natural-history data may be distributed across different institutions, using different assessments. Patient organisations may hold valuable insights into disease burden that are not fully represented in published research.

Understanding this landscape helps developers assess clinical trial feasibility, identify relevant experts, establish research collaborations and determine which evidence gaps need attention.

At Systemix Health, we see this broader understanding as an essential part of rare disease development. Scientific knowledge provides the foundation, but the clinical and organisational environment determines how research can be translated into a development programme.

The FDA's proposals reinforce the relevance of this approach, although important questions remain.

What European sponsors should put on the record by 11 December

The docket is open to any organisation, not only US companies. European sponsors with US ambitions have good reason to comment, because the framework will shape what evidence the FDA expects from programmes that are largely run in Europe.

Natural-history and registry data from European centres. Explain where your disease evidence sits, how it was collected and why it should count as fit-for-purpose for US review.

Alignment with EMA and the EU Joint Clinical Assessment. Ask the FDA to consider how its expectations line up with EMA scientific advice and JCA evidence requirements, so one development programme can serve both sides of the Atlantic.

How patients and experts are engaged. Describe how European patient organisations and expert reference network clinicians can contribute at defined milestones, and what support they would need.

Consistency between review divisions. Give concrete examples where different expectations created delay or rework, and propose what predictable guidance would look like.

Manufacturing and inspections. Where manufacturing sites are in Europe, set out how risk-based CMC review and pre-approval inspections could work for small-batch and complex biologics.

Comments can be submitted through Regulations.gov under docket FDA-2026-N-12214. Our article on the EU Joint Clinical Assessment covers the European side of the same evidence question.

Three areas that deserve more attention

1. From regulatory approval to patient access

Regulatory approval is a major achievement, but it does not guarantee that patients will receive a treatment.

For rare diseases, access often depends on factors beyond the regulatory review process.

Patients must first receive the correct diagnosis. Clinicians need to recognise when and where to refer them. Treatment centres require the appropriate expertise, facilities and capacity. Reimbursement decisions must also be addressed.

These challenges can be especially significant for advanced therapies requiring specialised administration and monitoring.

Although the FDA's initiative focuses primarily on development and regulatory review, developers also need to understand whether healthcare systems are prepared to deliver their treatments.

Mapping diagnostic pathways, specialist centres and potential access barriers early can help identify problems while there is still time to address them.

2. Making patient involvement practical

The framework's proposal to involve patients at defined milestones is encouraging, but implementation will matter.

Many rare disease patient organisations operate with limited resources. Meaningful participation in research and regulatory consultations requires time, expertise and preparation.

Clear information about when and how patient input is expected would help smaller organisations participate effectively.

It would also give sponsors greater certainty about how to integrate patient perspectives into their development programmes.

3. Creating transparent expert networks

External experts can strengthen regulatory decisions, particularly when published evidence is limited.

However, rare disease communities are small. The same specialists may be involved in academic research, patient registries, clinical trials and industry collaborations.

Transparent expert selection and appropriate conflict-of-interest management will therefore be important.

International collaboration also deserves attention. Many programmes depend on patients and specialist centres across several countries, making coordination with European research networks and regulators particularly relevant.

What pharmaceutical and biotechnology companies can do now

The proposed framework has not yet changed regulatory requirements, but it offers developers a reason to examine their existing strategies.

One question is particularly relevant: How well do you understand the disease ecosystem surrounding your therapy?

For rare disease developers, this involves more than knowing the underlying biology or identifying potential trial sites.

It means understanding how patients move through the healthcare system, where diagnoses are made, which specialists influence treatment decisions, what clinical evidence is available and which institutions have the capacity to support research and future treatment.

A detailed understanding of these factors can reveal development bottlenecks and opportunities for collaboration.

Sponsors can also contribute to the FDA's consultation process, drawing on practical experience with rare disease evidence generation and development challenges.

From scientific progress to patient access

The FDA's Rare Disease Framework Initiative recognises that rare diseases require development approaches tailored to their clinical realities.

Its emphasis on patient perspectives, external expertise and flexible evidence generation is a constructive direction. Whether the initiative delivers meaningful improvements will depend on how these principles are implemented.

For pharmaceutical and biotechnology companies, the broader lesson extends beyond regulatory approval.

Developing an effective therapy requires an understanding of the disease. Successfully developing and introducing that therapy also requires knowledge of the patients, clinical specialists, research institutions and healthcare systems surrounding it.

This is where Systemix Health supports rare disease developers.

We combine AI-powered research, specialist expertise and real-world insights to build a comprehensive understanding of rare disease landscapes. From scientific evidence and therapeutic development to patient pathways, treatment centres and stakeholder networks, we help pharmaceutical and biotechnology companies identify opportunities, anticipate bottlenecks and make better-informed development decisions.

Because understanding the disease is only the beginning. Understanding the system around it is what helps turn scientific progress into treatments that reach patients.

Explore our rare disease intelligence and system mapping services

Sources: US Food and Drug Administration, Fit-for-Purpose Rare Disease Framework Initiative; Public Meeting; Request for Information and Comments, Federal Register, 16 October 2026 (docket FDA-2026-N-12214); Akin Gump, client alert, 15 October 2026; Systemix Health Market Watch, issue 2; Regulatory Focus (RAPS), CDER approved 46 novel drugs in 2025, half for rare diseases, 13 January 2026.